in §351(k) of the Public Health Service Act. The FDA provides guidance documents detailing the expectations for protein product comparability, especially during manufacturing changes (see FDA Guidance).

In the European Union, the regulatory basis is grounded in the EU Regulation No 726/2004, which establishes the requirement for demonstrating comparability in terms of quality, safety, and efficacy for biosimilars. The EMA has clarified these expectations through various guidelines, including the “Guideline on Similar Biological Medicinal Products” (EMEA/CHMP/57819/2005).

The UK follows similar pathways post-Brexit, aligning closely with EU guidelines under the Medicines and Healthcare products Regulatory Agency (MHRA) regulations.

Documentation Requirements

Proper documentation is vital for supporting comparability claims and should address any changes in manufacturing processes. Relevant documentation often includes:

• Comparability protocol submissions outlining the scope of product changes.
• Analytical data demonstrating similar attributes—physicochemical properties, biological activity, and safety profiles.
• Quality Control and Quality Assurance documentation to substantiate manufacturing compliance.
• Clinical data, if required, to reinforce comparability assertions and address agency concerns regarding product integrity.

It is imperative that these documents are structured and detailed, following the ICH E6 and E3 rules on Good Clinical Practice and Clinical Study Reports respectively.

Review/Approval Flow

Initial Submission

The review process typically begins with an investigational new drug application (IND) when initiating a clinical trial or a BLA submission for marketing approval of the biosimilar. A well-drafted comparability protocol must be included that details how future process changes will be managed, addressing both pre and post-approval scenarios.

Addressing Failed Comparability

When faced with failed or inconclusive comparability results, it’s critical to conduct a thorough investigation into the root causes of discrepancies. Steps in the review and approval flow include:

• Re-evaluating analytical methods and processes involved in the comparison.
• Consulting with experienced regulatory affairs experts to assess necessary corrective actions.
• Preparing a comprehensive response delineating findings, implications, and rectifying strategies.

This response should ideally include additional data analyses, alternative analytical approaches, or even confirmatory clinical analyses if deemed necessary.

Common Deficiencies

During the review process, several common deficiencies can arise relating to comparability protocols:

• Insufficient Analytical Method Validation: Agencies often require robust demonstration that analytical methods used for comparability are validated for their intended purpose.
• Lack of Justification for Bridging Studies: If bridging studies are proposed post-failure, insufficient rationale can lead to rejections.
• Poor Data Presentation: Clarity and organization in data presentation are critical, as regulators expect data to be presented in a user-friendly manner that highlights key comparisons.

To avoid these deficiencies, companies should ensure comprehensive documentation and clear scientific justifications to support their arguments.

RA-Specific Decision Points

There are several critical decision points in regulatory strategy when handling biosimilar comparability related to process changes:

Variation vs. New Application

Determining whether to submit a variation or a new application is essential when significant changes are needed post-approval. Variations are suitable for changes that do not affect the overall clinical profile of the biosimilar, such as minor manufacturing changes or scale-ups. In contrast, a new application may be warranted when changes affect product safety or efficacy significantly.

Justifying Bridging Data

In cases where comparability outcomes fail, justifying the need for additional bridging studies becomes crucial. A robust scientific rationale that explains why bridging data is necessary and how it correlates with the existing data must be constructed. This includes detailed analyses of how changes will impact the safety and efficacy of the biosimilar and why existing data cannot conclusively demonstrate comparability.

Handling Agency Queries

When regulatory agencies issue queries regarding comparability protocols or process changes, companies should be prepared to answer comprehensively:

• Provide detailed explanations based on a thorough assessment of the data.
• Immediately address any irregularities uncovered during agency reviews or internal audits that may have led to these questions.
• Use a proactive approach to offer additional studies or data that can resolve concerns.

Conclusion

Handling failed or inconclusive comparability results for biosimilars is a complex aspect of regulatory affairs that necessitates a deep understanding of the relevant frameworks and guidelines. By meticulously addressing documentation, adhering to agency expectations, and strategically managing the review flow, regulatory professionals can navigate the challenges posed by process changes effectively. Continuous education and awareness of agency feedback can also significantly reduce deficiencies and ultimately support successful biosimilar approvals.